ArticleHaematologica2018
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.
Abstract readLetter
In one paragraph
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- IMGTAntibodies (Basel, Switzerland) · 2026Review
- Defective cell-autonomous signalling and antigenic polyreactivity of B-cell receptors from chronic lymphocytic leukaemia stereotyped subset 1.Nature communications · 2025Article
- Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.Leukemia · 2025Article
- Stereotyped B-Cell Receptor Immunoglobulins in B-Cell Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The Danish Lymphoid Cancer Research (DALY-CARE) Data Resource: The Basis for Developing Data-Driven Hematology.Clinical epidemiology · 2025Article
- Article
- [Biological characteristics and clinical significance of stereotyped B-cell receptor in chronic lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors.Genes · 2023Article
- Review
- Article
- Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin.Frontiers in oncology · 2021Review
- Review
- Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.Blood · 2019Article
- Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.Haematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Panagiotis BaliakasImmunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Mattias MattssonImmunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Anastasia HadzidimitriouInstitute of Applied Biosciences, Thessaloniki, Greece.
Eva MingaInstitute of Applied Biosciences, Thessaloniki, Greece.
Andreas AgathangelidisInstitute of Applied Biosciences, Thessaloniki, Greece.
Lesley-Ann SuttonImmunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Lydia ScarfoUniversità Vita-Salute San Raffaele, Milan, Italy.
Zadie DavisDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
Xiao-Jie YanThe Feinstein Institute for Medical Research, Northwell Health, New York, USA.
Karla PlevovaCEITEC-Central European Institute of Technology, MasarykBrno, Czech Republic.
Yorick SandbergDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Fie J VojdemanDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Tatiana TzenouFirst Department of Propaedeutic Medicine, University of Athens, Greece.
Charles C ChuThe Feinstein Institute for Medical Research, Northwell Health, New York, USA.
Silvio VeroneseMolecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Larry MansouriImmunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Karin E SmedbyDepartment of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Véronique GiudicelliIMGT®, the international ImMunoGeneTics information system®, Université de Montpellier, Laboratoire d'ImmunoGénétique Moléculaire LIGM, Institut de Génétique Humaine IGH, UPR CNRS 1142, Montpellier, France.
Florence Nguyen-KhacHematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
Panagiotis PanagiotidisFirst Department of Propaedeutic Medicine, University of Athens, Greece.
Gunnar JuliussonLund University and Hospital Department of Hematology, Lund Stem Cell Center, Sweden.
Achilles AnagnostopoulosHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Marie-Paule LefrancIMGT®, the international ImMunoGeneTics information system®, Université de Montpellier, Laboratoire d'ImmunoGénétique Moléculaire LIGM, Institut de Génétique Humaine IGH, UPR CNRS 1142, Montpellier, France.
Livio TrentinDepartment of Medicine, Hematology and Clinical Immunology Branch, Padova University School of Medicine, Italy.
Mark CatherwoodDepartment of Hemato-Oncology, Belfast City Hospital, Belfast, UK.
Marco MontilloMolecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Carsten U NiemannDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Anton W LangerakDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Sarka PospisilovaCEITEC-Central European Institute of Technology, MasarykBrno, Czech Republic.
Niki StavroyianniHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Nicholas ChiorazziThe Feinstein Institute for Medical Research, Northwell Health, New York, USA.
David OscierDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, UK.
Diane F JelinekDepartment of Immunology, Mayo Clinic, Rochester, MV, USA.
Tait ShanafeltDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Nikos DarzentasCEITEC-Central European Institute of Technology, MasarykBrno, Czech Republic.
Chrysoula BelessiHematology Department, Nikea General Hospital, Piraeus, Greece.
Frederic DaviHematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
Paolo GhiaUniversità Vita-Salute San Raffaele, Milan, Italy.
Richard RosenquistImmunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
Kostas StamatopoulosImmunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden kostas.stamatopoulos@gmail.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overDrug TherapyFemaleHumansImmunotherapyLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedRetrospective StudiesSurvival RateYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.